Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of (R,S)-Ampa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.68 |
| ▸ | GRIA3 | P42263 | 5/20 | 0.68 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.59 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.49 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.49 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.49 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,S)-Ampa SCHEMBL7200262 | 1.00 | GRIA1 (0.68) | GRIA1GRIA3GRIA2GRIA4BLM | |
| (R,S)-Ampa SCHEMBL68799 | 0.98 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4BLM | |
| (R,S)-Ampa SCHEMBL2458874 | 0.98 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4BLM | |
| (S)-Ampa SCHEMBL667915 | 0.98 | GRIA1 (0.69) | GRIA1GRIA3GRIA2GRIA4BLM | |
| (R,S)-Ampa SCHEMBL23242452 | 0.89 | GRIA1 (0.58) | GRIA1GRIA3GRIA2GRIA4BLM | |
| (R,S)-Ampa SCHEMBL19086372 | 0.89 | GRIA1 (0.58) | GRIA1GRIA3GRIA2GRIA4BLM | |
| (R,S)-Ampa SCHEMBL6553747 | 0.86 | GRIA1 (0.56) | GRIA1GRIA3GRIA2GRIA4BLM | |
| (S)-Ampa SCHEMBL28091565 | 0.84 | GRIA1 (0.53) | GRIA1GRIA3GRIA2GRIA4BLM | |
| SCHEMBL8812980 | 0.83 | GRIA1 (0.71) | GRIA1GRIA3GRIA2GRIA4BLM | |
| SCHEMBL8812978 | 0.83 | GRIA1 (0.71) | GRIA1GRIA3GRIA2GRIA4BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078308-A1 | GEL FORMULATION FOR TOPICAL OCULAR USE | GLUCOX BIOTECH AB (SE) | 2025-04-17 | — | — | WO | disclosed |
| US-20030050226-A1 | Dopamine analog amide | SHASHOUA VICTOR E (US) | 2003-03-13 | — | — | US | disclosed |
| US-6407137-B2 | A PRODRUG COMPOUND CAPABLE OF FACILITATING THE PASSAGE OF A DRUG ACROSS THE BLOOD BRAIN BARRIER COMPRISING A FATTY ACID COUPLED TO A DRUG TO FORM A PRODRUG | PROTARGA, INC. | 2002-06-18 | — | — | US | disclosed |
| US-20010056116-A1 | Dopamine analog amide | LUITPOLD PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | disclosed |
| US-6258836-B1 | FATTY ACID COUPLED TO ANTIAIDS SUBSTANCE, ANTIBIOTIC, CHOLINERGIC AGONIST AND OTHER USES FOR PASSING THE BLOOD BRAIN BARRIER | PROTARGA, INC. | 2001-07-10 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994392-A | PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER | NEUROMEDICA, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5409710-A | Foam cell drug delivery | ENDOCON, INC. (US) | 1995-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056116-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | GRIA1 596/4885GRIA3 339/4885GRIA2 609/4885 |
| US-20030050226-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | GRIA1 596/4885GRIA3 339/4885GRIA2 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.